brl-37344 and Urethral-Obstruction

brl-37344 has been researched along with Urethral-Obstruction* in 1 studies

Other Studies

1 other study(ies) available for brl-37344 and Urethral-Obstruction

ArticleYear
Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction.
    Neurourology and urodynamics, 2011, Volume: 30, Issue:7

    Beta3-adrenoceptor selective agonists are evaluated as a new treatment for patients with lower urinary tract symptoms . It is believed that β3-AR selective agonists exert their effects via a peripheral site of action. However, β3-ARs have been found in brain tissue. This study examined whether β3-ARs are present in rat sacral spinal cord, and whether there are differences in β3-AR expression between normal and partial urethral obstruction (PUO) animals, and furthermore assessed the functional relevance of spinal β3-ARs for micturition.. Thirty-eight male Sprague-Dawley rats underwent either PUO or sham-operation. Two weeks after operation, half of the animals were used for histomorphological analysis. Remaining animals were used for functional experiments, where a β3-AR selective agonist, BRL 37344, was given intrathecally. Bladder function was assessed by continuous cystometry in non-anesthetized animals before and after drug administration.. Beta3-ARs were found in sacral spinal cord segments with an accumulation in the ventral horn. There was a significant increase of β3-AR expression in obstructed rats. In functional experiments obstructed rats showed increased bladder weight, micturition frequency, spontaneous activity, and bladder pressures (all P < 0.05) compared to controls. Intrathecally administered BRL 37344 showed no effect in non-obstructed rats. In obstructed rats intrathecal BRL 37344 significantly reduced bladder pressures, spontaneous activity, and micturition frequency (all P < 0.05).. Beta3-ARs are present in rat sacral spinal cord, and are significantly up-regulated after PUO. Besides their well-established peripheral site of action in the treatment of voiding dysfunction, β3-AR selective agonists might exert relevant effects at a central nervous site of action.

    Topics: Adrenergic beta-3 Receptor Agonists; Animals; Blotting, Western; Disease Models, Animal; Ethanolamines; Immunohistochemistry; Male; Pilot Projects; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-3; Sacrum; Spinal Cord; Time Factors; Up-Regulation; Urethral Obstruction; Urinary Bladder; Urination; Urodynamics

2011